ARTICLE | Company News
EC approves Krystexxa pegloticase
January 9, 2013 1:24 AM UTC
The European Commission approved Krystexxa pegloticase from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) to treat severe chronic tophaceous gout in adult patients. The drug is indicated in patients who ...